AlphaMark Advisors LLC acquired a new stake in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 27,953 shares of the specialty pharmaceutical company’s stock, valued at approximately $559,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in AMAG. Advisors Asset Management Inc. raised its stake in shares of AMAG Pharmaceuticals by 791.6% in the second quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 52,356 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new stake in shares of AMAG Pharmaceuticals in the second quarter valued at $156,000. Meeder Asset Management Inc. raised its stake in shares of AMAG Pharmaceuticals by 590.9% in the second quarter. Meeder Asset Management Inc. now owns 8,947 shares of the specialty pharmaceutical company’s stock valued at $174,000 after acquiring an additional 7,652 shares in the last quarter. HighPoint Advisor Group LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at $188,000. Finally, NumerixS Investment Technologies Inc raised its stake in shares of AMAG Pharmaceuticals by 243.2% in the second quarter. NumerixS Investment Technologies Inc now owns 12,700 shares of the specialty pharmaceutical company’s stock valued at $257,000 after acquiring an additional 9,000 shares in the last quarter.
AMAG Pharmaceuticals stock opened at $17.57 on Wednesday. AMAG Pharmaceuticals, Inc. has a 1-year low of $11.95 and a 1-year high of $26.10. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.72 and a current ratio of 2.86. The firm has a market capitalization of $630.51 million, a price-to-earnings ratio of -3.08 and a beta of 0.23.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.11). AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. The business had revenue of $122.20 million during the quarter, compared to analyst estimates of $118.23 million. During the same quarter in the prior year, the business earned ($4.31) earnings per share. The firm’s quarterly revenue was down 1.7% on a year-over-year basis. As a group, analysts anticipate that AMAG Pharmaceuticals, Inc. will post -2.58 earnings per share for the current fiscal year.
Several analysts have recently issued reports on AMAG shares. BidaskClub upgraded AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 14th. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 price objective on shares of AMAG Pharmaceuticals in a research note on Friday, August 3rd. Cantor Fitzgerald reiterated a “hold” rating and issued a $18.00 price objective (up from $17.00) on shares of AMAG Pharmaceuticals in a research note on Friday, August 3rd. ValuEngine upgraded AMAG Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 3rd. Finally, B. Riley increased their price objective on AMAG Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, August 6th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $21.97.
ILLEGAL ACTIVITY NOTICE: “AlphaMark Advisors LLC Acquires Shares of 27,953 AMAG Pharmaceuticals, Inc. (AMAG)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/07/alphamark-advisors-llc-acquires-shares-of-27953-amag-pharmaceuticals-inc-amag.html.
AMAG Pharmaceuticals Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Recommended Story: Trading Penny Stocks
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.